- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00920647
A Safety and Dose Ranging Study of Idursulfase (Intrathecal) Administration Via an Intrathecal Drug Delivery Device in Pediatric Patients With Hunter Syndrome Who Have Central Nervous System Involvement and Are Receiving Treatment With Elaprase®
A Phase I/II, Randomized, Safety and Ascending Dose Ranging Study of Intrathecal Idursulfase-IT Administered in Conjunction With Intravenous Elaprase in Pediatric Patients With Hunter Syndrome and Cognitive Impairment
Elaprase (idursulfase), a large molecular protein, is not expected to cross the blood brain barrier at therapeutic levels when administered intravenously. A new formulation of idursulfase, idursulfase-IT, that differs from that of the intravenous (IV) formulation, Elaprase, has been developed to be suitable for delivery into the cerebrospinal fluid (CSF) via intrathecal administration.
This Phase I/II study is designed to obtain necessary safety and exposure data, as well as secondary and exploratory outcome measures, to be interpreted and used in the design of subsequent clinical trials.
Study Overview
Status
Conditions
Intervention / Treatment
Study Type
Enrollment (Actual)
Phase
- Phase 2
- Phase 1
Contacts and Locations
Study Locations
-
-
-
Birmingham, United Kingdom, B4 6NH
- Birmingham Children's Hospital
-
Birmingham, United Kingdom
- Birmingham Children's Hospital NHS Foundation Trust
-
-
-
-
North Carolina
-
Chapel Hill, North Carolina, United States, 27599
- University of North Carolina at Chapel Hill
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
1a. A deficiency in iduronate-2-sulfatase enzyme activity of ≤10 % of the lower limit of the normal range as measured in plasma, fibroblasts, or leukocytes (based on normal range of measuring laboratory) AND
1b. A documented mutation in the iduronate-2-sulfatase gene OR A normal enzyme activity level of one other sulfatase as measured in plasma, fibroblasts, or leukocytes (based on normal range of measuring laboratory).
2. The patient is male and is ≥3 and <18 years of age .
3. The patient has evidence at Screening of early stage (duration and severity metrics per protocol) Hunter syndrome-related Central Nervous System (CNS) involvement, defined as:
- The patient has an Intelligence quotient (IQ) ≤77 OR
There is evidence of a change of ≥1 but ≤2 standard deviations decline from a previous protocol-defined neurodevelopmental assessment. The duration of protocol-defined neurologic involvement is at least 3 months but less than 36 months as documented in the patient's medical history.
4. The patient has received and tolerated a minimum of 6 months of treatment with weekly intravenous idursulfase, and has received 80% of the total planned infusions within that time frame, including having received 100% of the planned infusions within 4 weeks immediately preceding the surgical insertion of the IDDD.
5. The patient must have sufficient auditory capacity, with or without aids, to complete the required protocol testing, and be compliant with wearing the aid on scheduled testing days.
6. The patient, patient's parent(s), or legally authorized guardian(s) must have voluntarily signed an Institutional Review Board / Independent Ethics Committee-approved informed consent form after all relevant aspects of the study have been explained and discussed with the patient. The guardians' consent must be obtained.
Exclusion Criteria:
- The patient has clinically significant non-Hunter syndrome-related CNS involvement which is judged by the Investigator to be likely to interfere with the accurate administration and interpretation of protocol assessments.
- The patient has an IQ ≥78
- The patient has a CNS shunt.
- The patient has experienced an infusion-related anaphylactoid event or has evidence of consistent severe adverse events related to treatment with Elaprase which, in the Investigator's opinion, may pose an unnecessary risk to the patient.
- The patient has any known or suspected hypersensitivity to anesthesia or is thought to be at an unacceptably high risk for anesthesia due to compromised airways or other conditions
- The patient has a history of complications from previous lumbar punctures or technical challenges in conducting lumbar punctures such that the potential risks would exceed possible benefits for the patient.
- The patient or patient's family has a history of neuroleptic malignant syndrome, malignant hyperthermia, or other anesthesia-related concerns.
- The patient has a history of poorly controlled seizure disorder.
- The patient has a significant medical or psychiatric comorbidity(ies) that might affect study data or confound the integrity of study results.
- The patient is currently receiving chronic psychotropic therapy (e.g., neuroleptics, benzodiazepines, antidepressants, anticonvulsants, stimulants, etc.) which in the Investigator's opinion would likely affect the neurocognitive assessments. Intermittent use of selected short half-life agents (benzodiazepine, sedatives, etc.) may be permitted as long as there are 5 half-lives between last drug administered and study-related procedures including neurocognitive assessments.
- The patient has received treatment with any investigational drug or device within the 30 days prior to study entry.
- The patient has received a cord blood or bone marrow transplant at any time, or has received blood product transfusions within 90 days prior to Screening.
- The patient is unable to comply with the protocol, (e.g., has significant hearing or vision impairment, a clinically relevant medical condition making implementation of the protocol difficult, unstable social situation, known clinically significant psychiatric/behavioral instability, is unable to return for safety evaluations, or is otherwise unlikely to complete the study), as determined by the Investigator.
- The patient has skeletomuscular/spinal abnormalities or other contraindications for the surgical implantation of the IDDD.
- The patient has an opening CSF pressure upon lumbar puncture that exceeds 30 cm H2O(water) .
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Other: Control
Untreated Patients
|
3 dose cohorts were planned.
Within each dose cohort, patients will be randomized to 1 of 2 treatment options: treatment with study drug or no treatment with 4 treated patients per dose group and a total of 4 untreated patients (1-2 untreated patients will be assigned in each dose cohort).
They will not undergo surgical placement of an Intrathecal Drug Delivery Device (IDDD), and will not receive Idursulfase-IT.
|
Experimental: Idursulfase -IT (1 mg)
monthly using an intrathecal drug delivery device (IDDD)
|
The original design of the study was to test the dose levels of 10, 30 and 100 mg.
This was based on a calculation of a minimally effective dose around 10 mg, with subsequent dose levels being chosen as increasing half-log steps.
During the conduct of the study; however, it became clear that the 10 mg dose elicited a strong Pharmacodynamic response, as measured by a dramatic and sustained drop in the CSF GAG levels.
This indicated the need to explore a lower level as a minimally effective dose level, leading to the introduction of the 1 mg group.
Enrollment of patients in this dose cohort will commence after the last patient has been enrolled in 30 mg dose cohort.
4 patients will be undergo surgical placement of an IDDD and receive 1 mg idursulfase-IT as an IT injection via an IDDD once per month (ie, every 28 days) for 6 month.
|
Experimental: Idursulfase-IT (10 mg)
monthly using an intrathecal drug delivery device (IDDD)
|
Patients will be enrolled in 10 mg dose cohort and 30 mg dose cohort in a sequential, escalating fashion.
4 patients will undergo surgical placement of an IDDD and receive 10 mg idursulfase-IT as an intrathecal (IT) injection via an IDDD once per month (ie, every 28 days) for 6 month.
|
Experimental: Idursulfase -IT (30 mg)
monthly using an intrathecal drug delivery device (IDDD)
|
Patients will be enrolled in 10 mg dose cohort and 30 mg dose cohort in a sequential, escalating fashion.
4 patients will undergo surgical placement of an IDDD and receive 30 mg idursulfase-IT as an IT injection via an IDDD once per month (ie, every 28 days) for 6 month.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Number of Serious Adverse Event (SAE)
Time Frame: 6 months
|
6 months
|
|
Number of Treatment Emergent Adverse Event (AE)
Time Frame: Baseline to week 23
|
ITT patient population
|
Baseline to week 23
|
Safety Changes in Cerebrospinal Fluid (CSF)- White Blood Cells (WBC)
Time Frame: 6 months
|
White blood cell count in CSF was monitored throughout the study as a way of assessing any potential inflammation of the meninges induced by idursulfase-IT.
|
6 months
|
Safety: Development of Anti-idursulfase Antibodies (CSF)
Time Frame: 6 months
|
Reflects development of anti-idursulfase antibodies post baseline.
|
6 months
|
Safety: Development of Anti-idursulfase Antibodies (Serum)
Time Frame: 6 months
|
6 months
|
|
Clinically Significant ECG Findings at Any Time During the Study.
Time Frame: 6 months
|
Electrocardiogram (ECG) parameters included: heart rate, sinus rhythm, atrial/ventricular hypertrophy, PR, QRS, QT and QTc intervals.
|
6 months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change From Baseline in CSF Glycosaminoglycans [GAGs] at Week 27
Time Frame: Baseline to Week 27
|
Percent Change from Baseline to Week 27
|
Baseline to Week 27
|
Level of Idursulfase in the CSF Compartment Resulting From Monthly Idursulfase IT Administrations
Time Frame: Week 27 (end of study)
|
Samples collected from patients treated at doses of 1 mg and 30 mg, as well as the control group, were below the lower limit of detection of the bioanalytical method (3.13 ng/mL)
|
Week 27 (end of study)
|
Concentration of Idursulfase in Serum After Single Administration (Week 3) in Conjunction With Elaprase
Time Frame: Weeks 3
|
Values below lower limit of quantitation (LLOQ) are listed as 0.
|
Weeks 3
|
Concentration of Idursulfase in Serum After Repeated Doses of Intrathecal Idursulfase-IT Given in Conjunction With Elaprase
Time Frame: Weeks 23
|
Weeks 23
|
|
% Change From Baseline in Urinary GAG
Time Frame: Baseline to Week 27
|
Baseline to Week 27
|
Collaborators and Investigators
Sponsor
Publications and helpful links
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
- enzyme replacement therapy
- lysosomal storage disorder
- lysosomal storage disease
- mps symptoms
- enlarged adenoids
- elaprase
- hunter's syndrome
- hunters disease
- hunter's disease treatment
- hunter syndrome therapy
- iduronate sulfatase
- mps society
- hunter syndrome treatment
- hunter's disease
- iduronate 2 sulfatase
- mucopolysaccharides
- mps diagnosis
- chronic ear infection
- hunters syndrome
- ert treatment
- hunter disease
- idursulfase
- hunter's syndrome treatment
- Mucopolysaccharidosis (mps) 2
- Mucopolysaccharidosis (mps) ii
- Mucopolysaccharidosis(MPS) II
- Mucopolysaccharidosis(MPS)2
Additional Relevant MeSH Terms
- Pathologic Processes
- Metabolic Diseases
- Nervous System Diseases
- Neurologic Manifestations
- Neurobehavioral Manifestations
- Disease
- Genetic Diseases, Inborn
- Genetic Diseases, X-Linked
- Connective Tissue Diseases
- Carbohydrate Metabolism, Inborn Errors
- Metabolism, Inborn Errors
- Lysosomal Storage Diseases
- Mucinoses
- Mental Retardation, X-Linked
- Intellectual Disability
- Heredodegenerative Disorders, Nervous System
- Mucopolysaccharidoses
- Syndrome
- Mucopolysaccharidosis II
Other Study ID Numbers
- HGT-HIT-045
- 2010-020048-36 (EudraCT Number)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
IPD Sharing Access Criteria
IPD Sharing Supporting Information Type
- Study Protocol
- Statistical Analysis Plan (SAP)
- Informed Consent Form (ICF)
- Clinical Study Report (CSR)
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Hunter Syndrome
-
CENTOGENE GmbH RostockTerminatedMucopolysaccharidosis II | Hunter Syndrome | Hunter's Syndrome, Mild Form | Hunter's Canal SyndromeMexico
-
TakedaRecruiting
-
TakedaAvailableHunter SyndromeUnited States, Australia, Mexico, Spain, United Kingdom
-
Green Cross CorporationCompleted
-
ShireActive, not recruitingHunter SyndromeUnited States, Spain, Canada, United Kingdom, Mexico, Australia, France
-
ShireCompleted
-
Green Cross CorporationUnknown
-
Green Cross CorporationUnknownThe Long-term Safety Study of Idursulfase-beta in Hunter Syndrome(Mucopolysaccharidosis II) PatientsHunter SyndromeKorea, Republic of
-
ShireCompletedHunter SyndromeUnited States, United Kingdom
Clinical Trials on Control
-
Claudia M. WittCompleted
-
University of California, San FranciscoWithdrawn
-
Universidad Nacional de Educación a DistanciaMinisterio de Economía y Competitividad, SpainUnknownChronic Pain | FibromyalgiaSpain
-
University of California, Los AngelesThe National Council on Aging; City of Los Angeles Department of Aging; Los Angeles...Completed
-
Queen's University, BelfastPublic Health Agency, Health and Social Care Research and Development; Tiny...Completed
-
National Taiwan University HospitalEnrolling by invitationCognitive Function | Atrial Fibrillation, PersistentTaiwan
-
Takeshi MorimotoUniversity of the RyukyusActive, not recruitingCoronary Artery Disease | Hypertension | Type 2 Diabetes | DyslipidemiaJapan
-
Johnson & Johnson Vision Care, Inc.TerminatedRefractive Error CorrectionUnited States
-
Vanderbilt University Medical CenterCompleted
-
Yonsei UniversityNot yet recruitingHypertension | Chronic Kidney Diseases | DyslipidemiasKorea, Republic of